Pharmaceutical Drug Delivery Market: Global Industry Analysis and Forecast (2023-2029)

Pharmaceutical Drug Delivery Market size was valued at USD 2.03 Bn. in 2022 and the total Pharmaceutical Drug Delivery revenue is expected to grow by 7 % from 2023 to 2029, reaching nearly USD 3.26 Bn.
Pharmaceutical Drug Delivery Market Overview:
A pharmaceutical drug delivery system (DDS) is a formulation or device used to provide a medicinal ingredient to the body. This method works by delivering pharmaceuticals to particular portions of the body via the assistance medium, which can regulate the delivery of the therapy via a physiological or chemical trigger. DDS is used to introduce drug delivery systems into the body, such as oral drug delivery, pulmonary drug delivery, injectable drug delivery, nasal drug delivery, and others, in order to increase the efficacy and safety of an administration.

The rise in awareness about the utilization of pharmaceutical drug delivery systems is a significant factor driving the growth of the pharmaceutical drug delivery industry. Additionally, other factors such as increased health-care spending and increased government funding for drug-delivery research boost the growth of the pharmaceutical drug delivery business. Moreover, the increasing incidence of numerous chronic illnesses, which necessitate the usage of pharmaceutical drug delivery systems, is a key driver driving market growth. An increase in the amount of prescription recalls and drug failures are limiting the pharmaceutical drug delivery market's development. In contrast, strong potential development in developing economies is likely to provide attractive possibilities during the forecast period.
Report Scope:
The report on Pharmaceutical Drug Delivery provides a quantitative analysis of market size, price, M&A, demand, and supply chain, investment and expansion plans by key competitors, and predictions. Porter's five forces study explains how buyers and suppliers build supplier-buyer networks and make profit-driven decisions. The present Pharmaceutical Drug Delivery Market potential is assessed through detailed analysis and segmentation. The analysis will provide investors with a full insight into the industry's future, as well as the elements likely to affect the firm favorably or adversely.

The research offers a complete understanding of the market for those investors wishing to invest. This study contains scenarios for the Pharmaceutical Drug Delivery Market from the past and present, along with projected market numbers. The report's thorough analysis of important competitors, including market leaders, followers, and new entrants, covers every aspect of the market. The research contains strategic profiles of the top market participants, a full examination of their key competencies, and their company-specific plans for the introduction of new products, growth, partnerships, joint ventures, and acquisitions. With its clear portrayal of competitive analysis of significant companies by product, pricing, financial condition, product portfolio, growth strategies, and regional presence in the domestic as well as the local market, the research acts as an investor's guide.To know about the Research Methodology :- Request Free Sample Report
Pharmaceutical Drug Delivery Market Dynamics:
Market Drivers:

Increased Patient Shift Towards Advanced Drug Delivery Systems to Benefit Market Growth

The increased shift of patients toward advanced products is attributable to lower variability in systemic medication concentrations and the capacity to administer a medicine more selectively and accurately to a specific spot. Patients are increasingly using self-administered devices as a result of these qualities. For example, Idorsia teamed with Antares in November 2019 to create a unique self-administered medication device product for Selatogrel. Moreover, the digitization of medical equipment has raised patient awareness of modern goods.

The digitalization method offers several benefits, including needle-free injection, regulated dose, and increased self-administration flexibility, resulting in increased device acceptance. Medtronic announced the release of Efficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery devices, in January 2020. This program enabled doctors to better efficiently manage their focused medication administration methods while treating patients with chronic pain, cancer pain, and severe spasticity. Patient preferences for sophisticated goods, together with greater government measures to raise public knowledge of the items, are projected to drive the industry forward in the forecast years.



Increasing Burden of Chronic Diseases

Asthma, Chronic Obstructive Pulmonary Disease (COPD), cancer, diabetes, and other illnesses have been the top causes of mortality globally. Factors such as the growing incidence of chronic diseases such as diabetes, COPD, and asthma, as well as new treatments for chronic diseases, are likely to drive the market during the forecast period. According to the European Commission's 2020 Ageing Report, the percentage of individuals aged 65 and more in European Union nations is expected to grow from 21.8% in 2016 to 53.2% in 2070. The fact that such a high proportion of the senior population is sensitive to chronic illnesses is likely to promote the uptake of such systems. Additionally, the increased launch of new goods and digitization in the healthcare industry have created the potential for growth for the firms.

Research and developments in pharmaceutical and drug delivery system

Companies such as Evonik (Germany) have undertaken many strategic advancements in recognition of the potential for biologics production. For example, in 2022, the business doubled its production capacity by purchasing SurModics, which specializes in controlled-release parenteral applications. Evonik has bought complementary technologies, such as Boehringer Ingelheim's RESOMER platform, to strengthen its position in this industry. Similarly, WuXi Biologics announced the establishment of WuXi Vaccines in 2019, a joint venture with Shanghai Hile Bio-Technology Co., Ltd. The firms formed a strategic alliance in which WuXi Vaccines would construct a specialized facility and offer a commercial product to the worldwide market. The biopharmaceutical sector has seen the birth of a new class of therapies with tremendous potential in cancer, diabetes, and other disease areas.

Market Restraints:

The possibility of needlestick injuries

Needlestick injuries are one of the most significant hazards to one's health and safety:

According to PharmaJet, between 600,000 to 800,000 needlestick injuries are recorded in the United States each year. Additionally, according to the Occupational Safety and Health Administration (OSHA), about 5.7 million employees in the United States are at risk of being exposed to blood-borne pathogens as a result of needlestick injuries. The CDC estimates that 385,000 needlestick injuries occur in US hospital settings each year. Similarly, over 1 million needlestick injuries are recorded each year in Europe (Source: Becton, Dickinson, and Company).

Price competition

Governments in both developed and developing nations are advocating cost-cutting initiatives such as lowering prescription reimbursement costs and increasing the usage of generics. Drug producers throughout the world are under enormous cost-cutting pressure from governments, insurers, and patients. This lower pricing pressure is leading to increased medication acceptance in emerging economies, where there is a considerable need for low-cost treatments. This, however, has a negative impact on the profitability of various pharmaceutical businesses. This trend is expected to continue in the coming years due to ongoing pressure from insurers, pharmacy benefit managers (PBMs), and public and private payers to reduce pharmaceutical prices due to concerns about covering more new medicines to treat common conditions such as high cholesterol and diabetes.

Market Opportunities:

Biosimilars and biologics are in high demand

Biosimilars are more acceptable for the treatment of non-life-threatening chronic disorders. Furthermore, biosimilars have the potential to drive the total therapeutics industry by allowing patients to obtain pharmaceuticals at lower costs. The decreased production cost as a result of the adoption of current manufacturing methods for the creation of biosimilars is a significant factor projected to drive the growth of this market in the future years. In addition, an increasing number of firms are performing biosimilar clinical studies. Biocon Limited, for example, is participating in clinical studies for a variety of medications, including Insulin Glargine, Trastuzumab, Bevacizumab, Pegfilgrastim, and Adalimumab. Amgen Inc. is also undertaking clinical studies for a number of biosimilars, including rituximab, infliximab, centuximab, eculizumab, and trastuzumab. Zarxio (Sandoz), AMJEVITA (Amgen Inc.), and Erelzi are among the FDA-approved biosimilars (Sandoz). The Biosimilar Initiative Development (BPD) program had around 79 programs engaged as of March 2020.

Strategic Partnerships and New Product Launches to Accelerate Market Growth

Companies in the industry are continually focusing on tactics such as collaboration and the creation and release of new goods. These tactics assist businesses in increasing their income, hence pushing the total market growth. The introduction of new products with enhanced safety and user-friendliness is likely to entice the large pharmaceutical business. Furthermore, improved dosage characteristics complement pharmacological treatment outcomes and expand the possibility for illness management in home care settings. For example, Ypsomed announced YpsoMate in November 2022, claiming it to be the world's first auto-injector for prefilled syringes with an integrated connection. It is suitable for self-administration. Furthermore, there is an increase in market participants collaborating with pharmaceutical corporations to develop and commercialize goods. KINDEVA DRUG DELIVERY, for example, partnered with Cambridge Healthcare Innovations Limited (CHI) in April 2022 to develop and market CHI's Aeolus dry-powder inhaler (DPI) platform technology.
Pharmaceutical Drug Delivery Market Segment Analysis:
Based on Route of administration, the Oral Drug Delivery segment is expected to grow at the highest CAGR during the forecast period. Because of advantages such as the comfort of drug administration via the oral route, patient choice, cost-effectiveness, and ease of large-scale manufacture of oral dosage forms, oral medicine is the most prevalent way of drug administration. Approximately 60% of established small-molecule medication compounds on the market are taken orally. According to current estimates, oral formulations account for over 90% of the worldwide market share of all pharmaceutical formulations designed for human consumption. Orally given pharmaceutical goods account for around 84% of the best-selling pharmaceutical items and are presently valued at $35 billion, with a 10% annual growth rate.

Patients are more likely to comply with oral formulations than with alternative parenteral methods such as intravenous, subcutaneous, and intramuscular injections, as well as inhalation for asthma treatments (Ingersoll and Cohen). Additionally, orally delivered medications can be directed to specific sections of the GI tract for the localized treatment of pathological illnesses such as stomach and colorectal malignancies, infections, inflammations, bowel diseases, gastro-duodenal ulcers, and gastroesophageal reflux problems.



Based on Application, the Infectious Diseases segment is expected to grow at the highest CAGR during the forecast period. The rising frequency of infectious illnesses throughout the world is a significant factor driving the market growth. Additionally, the COVID-19 pandemic situation has raised market R&D investment for novel treatments, as has the increase in FDA approvals for such drugs, accelerating the market growth of this category.

Additionally, the cancer segment is expected to develop considerably throughout the forecast period. This is owing to the increased frequency of cancer in the population. According to the International Agency for Research on Cancer, around 19.5 million new cancer cases and 12 million cancer deaths were recorded worldwide in 2020. Cancer cases worldwide are expected to increase by 49% between 2020 and 2040. Globally, 28.6 million instances are projected by 2040. Breast cancer, lung cancer, bowel cancer, and womb cancer are the most common kinds of cancer that harm humans.

The cardiovascular category, on the other hand, is expected to be the fastest-growing segment during the forecast period. This is owing to pharmaceutical firms' increased emphasis on developing medications to treat cardiovascular illnesses. Moreover, the growing incidence of cardiovascular illnesses as a result of bad eating habits, growing obesity, increased alcohol use, and physical inactivity is increasing the number of cardiovascular disease-related fatalities. CVDs accounted for 33% of worldwide fatalities in 2019, according to the World Health Organization.

Based on Facility of Use, In 2022, the hospital’s segment have the highest revenue share. This is owing to the increased penetration of private and governmental hospitals worldwide. Growing government and corporate sector investments in the establishment of modern hospitals have fueled the growth of this category. The growing number of hospital admissions as a result of illness burden is supporting the growth of this category globally.

The home care settings category, on the other hand, is expected to be the most potential market during the forecast period. The growing geriatric population, increasing personal disposable income, increased awareness of hospital-acquired illnesses, and growing healthcare spending are the primary drivers expected to fuel the growth of the home care settings segment.
Pharmaceutical Drug Delivery Market Regional Insights:
With a 45.8% market share, North America was the top regional market in 2022. Government initiatives to support the development of pharmaceutical drug delivery and growing R&D spending are expected to drive market growth in this region. Additionally, the existence of important market participants in pushing the use of pharmaceutical drug medication delivery systems. The growing prevalence of chronic illnesses such as cancer, diabetes, and cardiovascular disease is boosting market growth. One of the important factors driving the regional market growth is the increasing use of pharmaceutical drug delivery medication systems for the treatment of hypertension.

Europe accounted for the second-largest market share in 2022 as a result of increased R&D activity and the presence of significant pharmaceutical businesses in the area. With an increase in patients suffering from chronic diseases such as cancer, diabetes, and COPD, the regional market is expected to develop steadily in the forecast period. During the forecast period, Asia Pacific is expected to have the greatest CAGR. The region is getting international prominence as the pharmaceutical sector develops. Rapid growth in the Indian and Chinese pharmaceutical sectors is benefiting the region's industry. Another key element driving product acceptance in Japan is the country's high senior population.
Pharmaceutical Drug Delivery Market Scope: Inquire before buying



Pharmaceutical Drug Delivery Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 2.03 Bn.


Forecast Period 2023 to 2029 CAGR:
7%
Market Size in 2029:
US $ 3.26 Bn.


 Segments Covered:
by Route of Administration
• Oral Drug Delivery
• Injectable Drug Delivery
• Topical Drug Delivery
• Ocular Drug Delivery
• Pulmonary Drug Delivery
• Implantable Drug Delivery
• Transmucosal Drug Delivery
• Nasal Drug Delivery


by Application
• Infectious Diseases
• Cancer
• Cardiovascular Diseases
• Diabetes
• Respiratory Diseases
• Central Nervous System Disorders
• Autoimmune Diseases
• Other Applications


by Facility of Use
• Hospitals
• Ambulatory Surgery Centers
• Home Care Settings
• Diagnostic Centers
• Other



Pharmaceutical Drug Delivery Market by Region
• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)
Pharmaceutical Drug Delivery Market Key Players
• Johnson & Johnson
• Novartis International AG
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Bayer AG
• Antares Pharma, Inc.
• Becton
• Dickinson and Company
• GlaxoSmithKline plc
• 3M
• Merck & Co., Inc.
• Sanofi
• Amgen, Inc.
• AbbVie Inc.
• Genmab A/S
• Gilead Sciences, Inc.
• Boehringer Ingelheim
• AstraZeneca plc.
• Eli Lilly and Company
• Teva Pharmaceuticals Industries Ltd.
• Bristol-Myers Squibb
• Gerresheimer AG
• Boston Scientific Corporation
• Nimbus Therapeutics
• Kite Pharma
• IDEAYA Biosciences

Frequently Asked Questions:

1] What segments are covered in the Global Pharmaceutical Drug Delivery Market report?
Ans. The segments covered in the Pharmaceutical Drug Delivery Market report are based on Route of Administration, Application, Facility of Use, and region.

2] Which region is expected to hold the highest share in the Global Pharmaceutical Drug Delivery Market?
Ans. The North America region is expected to hold the highest share in the Pharmaceutical Drug Delivery Market.

3] What is the market size of the Global Pharmaceutical Drug Delivery Market by 2029?
Ans. The market size of the Pharmaceutical Drug Delivery Market by 2029 is expected to reach US$ 3.26 Bn.

4] What is the forecast period for the Global Pharmaceutical Drug Delivery Market?
Ans. The forecast period for the Pharmaceutical Drug Delivery Market is 2023-2029.

5] What was the market size of the Global Pharmaceutical Drug Delivery Market in 2022?
Ans. The market size of the Pharmaceutical Drug Delivery Market in 2022 was valued at US$ 2.03 Bn.